Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort
Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort
复制标题
DOI：
10.1016/j.ijom.2015.06.015
复制
发表时间：
2015-12-01
影响因子：
2.4
通讯作者：
Sun, G.
中科院分区：
文献类型：
--
作者：
Jiang, X.;Zhang, Y.;Sun, G.
本研究的目的是探讨大蒜素治疗II期口腔黏膜下纤维化（OSF）在中国患者队列中的有效性和安全性。进行随机临床试验。每周一次局部注射曲安奈德（TA）或大蒜素，连续16周。评估了口腔张开、烧灼感和口腔健康相关生活质量的改善。48名受试者完成研究，无明显不良反应。40周时，TA组净增口量为2.27 +/- 0.84 mm，蒜素组净增口量为5.16 +/- 1.04 mm。TA组烧灼感改善2.79 +/- 0.87，大蒜素组烧灼感改善4.33 +/- 1.04。TA组OBIP-14评分提高4.67 +/- 2.94分，大蒜素组OBIP-14评分提高12.58 +/- 9.82分。大蒜素局部注射改善了这些II期OSF患者的开口、烧灼感和口腔健康相关生活质量。大蒜素是一种潜在的辅助治疗药物。
The objective of this study was to investigate the efficacy and safety of allicin in the treatment of stage II oral submucous fibrosis (OSF) in a Chinese patient cohort. A randomized clinical trial was performed. Triamcinolone acetonide (TA) or allicin was injected intralesionally weekly for 16 weeks. Improvements in mouth opening, burning sensation, and oral health-related quality of life were evaluated. Forty-eight subjects completed the study without obvious adverse reactions. At 40 weeks, the net gain in mouth opening was 2.27 +/- 0.84 mm in the TA group and 5.16 +/- 1.04 mm in the allicin group. Burning sensation improved by 2.79 +/- 0.87 in the TA group and by 4.33 +/- 1.04 in the allicin group. The OBIP-14 score improved by 4.67 +/- 2.94 in the TA group and by 12.58 +/- 9.82 in the allicin group. Allicin intralesional injections improved mouth opening, burning sensation, and oral health-related quality of life in these stage II OSF patients. Allicin appears to be a potential adjunctive therapeutic drug.